Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 42INDUSTRY 11NIH 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 19Lymphoma 3Neoplasms, Plasma Cell 2Smoldering Multiple Myeloma 1Sezary Syndrome 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Rituximab 8Vincristine 5Doxorubicin 5Cyclophosphamide 5Methotrexate 4Cytarabine 4Bortezomib 4Radiotherapy 3Prednisone 3Bendamustine Hydrochloride 3Peripheral Blood Stem Cell Transplantation 2Melphalan 2Leucovorin 2Dexamethasone 2CT-P10 2zanubrutinib 1obinutuzumab 1merphos 1liposomal amphotericin B 1ixabepilone 1ibritumomab tiuxetan 1fludarabine phosphate 1carmustine, poliferprosan 20 drug combination 1alvocidib 1acalabrutinib 1Whole-Body Irradiation 1Watchful Waiting 1Vancomycin 1Tazobactam 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma, Mantle-Cell × Lenalidomide × Clear all
NCT01415752 2025-04-08

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
373 enrolled 14 charts
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡